Variation in Opioid Prescribing and Use for Acute Pain in Diverse Populations

Completed

Conditions studied: Opioid Use, Opioid Prescribing

In brief

This study will characterize patient pain and opioid use after an initial opioid prescription for acute pain.

Key facts

Study ID

NCT04509115

Run by

Yale University

People needed

1709

Starts

2020-09-11

Expected to finish

2023-11-30

Last updated by the study team

2023-12-05

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• English- or Spanish-speaking
• Experiencing acute pain of less than 8 weeks duration at the time the opioid is prescribed
• Received prescription for opioid analgesic at visit; opioids included in the study will be all FDA-approved enteral, transdermal, and transmucosal opioid analgesics including the most common: hydrocodone (except cough and anti-diarrheal medications), oxycodone, codeine (except cough medications), tramadol, morphine, hydromorphone. Receipt of a prescription for the following is not an exclusion: buprenorphine (as an analgesic), butorphanol, dihydrocodeine, fentanyl, meperidine, methadone (as an analgesic), oxymorphone, pentazocine, sufentanil, and tapentadol. All of these opioids are included in any combinations with acetaminophen, aspirin, ibuprofen, naloxone, etc.
• Self-report of no opioid use (no use of prescribed opioids or illicit opioids, including medical or non-medical use) in the past 6 months
• Willing and able to give consent and participate in study
• Able to access a device with web access (laptop, desktop, smartphone, or tablet) daily to complete study surveys
• Willing to connect Fitbit to a mobile device (smartphone or tablet) that can regularly link to Hugo for data transfer
• Willing to use the health data sharing platform
• Released/discharged to home after their visit.

You may not qualify if…

• Pain thought to be caused by a systemic disease very likely to progress to chronic pain (e.g., sickle cell disease, fibromyalgia, lupus, multiple sclerosis, etc.);
• Cancer or end-of-life pain;
• Unable to give consent and be enrolled within 3 days of their visit.

Where it is running

• University of Alabama Birmingham — Birmingham, Alabama, United States
• Cedars Sinai — Los Angeles, California, United States
• Yale-New Haven Health — New Haven, Connecticut, United States
• Mayo Clinic — Rochester, Minnesota, United States
• Monument Health — Rapid City, South Dakota, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.